173 related articles for article (PubMed ID: 35158113)
1. Dysregulated lipid metabolism blunts the sensitivity of cancer cells to EZH2 inhibitor.
Zhang T; Guo Z; Huo X; Gong Y; Li C; Huang J; Wang Y; Feng H; Ma X; Jiang C; Yin Q; Xue L
EBioMedicine; 2022 Mar; 77():103872. PubMed ID: 35158113
[TBL] [Abstract][Full Text] [Related]
2. Blocking EZH2 methylation transferase activity by GSK126 decreases stem cell-like myeloma cells.
Zeng D; Liu M; Pan J
Oncotarget; 2017 Jan; 8(2):3396-3411. PubMed ID: 27926488
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of an EZH2 inhibitor in patient-derived orthotopic xenograft models of pediatric brain tumors alone and in combination with chemo- and radiation therapies.
Qi L; Lindsay H; Kogiso M; Du Y; Braun FK; Zhang H; Guo L; Zhao S; Injac SG; Baxter PA; Su JM; Xiao S; Erickson SW; Earley EJ; Teicher B; Smith MA; Li XN
Lab Invest; 2022 Feb; 102(2):185-193. PubMed ID: 34802040
[TBL] [Abstract][Full Text] [Related]
4. PTEN Is Fundamental for Elimination of Leukemia Stem Cells Mediated by GSK126 Targeting EZH2 in Chronic Myelogenous Leukemia.
Zhou J; Nie D; Li J; Du X; Lu Y; Li Y; Liu C; Dai W; Wang Y; Jin Y; Pan J
Clin Cancer Res; 2018 Jan; 24(1):145-157. PubMed ID: 29070525
[No Abstract] [Full Text] [Related]
5. Inhibition of EZH2 and activation of ERRγ synergistically suppresses gastric cancer by inhibiting FOXM1 signaling pathway.
Huang B; Mu P; Yu Y; Zhu W; Jiang T; Deng R; Feng G; Wen J; Zhu X; Deng Y
Gastric Cancer; 2021 Jan; 24(1):72-84. PubMed ID: 32529327
[TBL] [Abstract][Full Text] [Related]
6. ABCB1 and ABCG2 restrict the brain penetration of a panel of novel EZH2-Inhibitors.
Zhang P; de Gooijer MC; Buil LC; Beijnen JH; Li G; van Tellingen O
Int J Cancer; 2015 Oct; 137(8):2007-18. PubMed ID: 25868794
[TBL] [Abstract][Full Text] [Related]
7. Targeting EZH2 Enhances Antigen Presentation, Antitumor Immunity, and Circumvents Anti-PD-1 Resistance in Head and Neck Cancer.
Zhou L; Mudianto T; Ma X; Riley R; Uppaluri R
Clin Cancer Res; 2020 Jan; 26(1):290-300. PubMed ID: 31562203
[TBL] [Abstract][Full Text] [Related]
8. Enhancer of zeste homolog 2 (EZH2) regulates adipocyte lipid metabolism independent of adipogenic differentiation: Role of apolipoprotein E.
Yiew NKH; Greenway C; Zarzour A; Ahmadieh S; Goo B; Kim D; Benson TW; Ogbi M; Tang YL; Chen W; Stepp D; Patel V; Hilton R; Lu XY; Hui DY; Kim HW; Weintraub NL
J Biol Chem; 2019 May; 294(21):8577-8591. PubMed ID: 30971429
[TBL] [Abstract][Full Text] [Related]
9. Targeting PRC2 for the treatment of cancer: an updated patent review (2016 - 2020).
Dockerill M; Gregson C; O' Donovan DH
Expert Opin Ther Pat; 2021 Feb; 31(2):119-135. PubMed ID: 33103538
[TBL] [Abstract][Full Text] [Related]
10. Chromatin remodeling by the histone methyltransferase EZH2 drives lung pre-malignancy and is a target for cancer prevention.
Tellez CS; Picchi MA; Juri D; Do K; Desai DH; Amin SG; Hutt JA; Filipczak PT; Belinsky SA
Clin Epigenetics; 2021 Feb; 13(1):44. PubMed ID: 33632299
[TBL] [Abstract][Full Text] [Related]
11. EZH2 inhibition promotes epithelial-to-mesenchymal transition in ovarian cancer cells.
Cardenas H; Zhao J; Vieth E; Nephew KP; Matei D
Oncotarget; 2016 Dec; 7(51):84453-84467. PubMed ID: 27563817
[TBL] [Abstract][Full Text] [Related]
12. EZH2: a novel target for cancer treatment.
Duan R; Du W; Guo W
J Hematol Oncol; 2020 Jul; 13(1):104. PubMed ID: 32723346
[TBL] [Abstract][Full Text] [Related]
13. Enhancer of zeste homologue 2 plays an important role in neuroblastoma cell survival independent of its histone methyltransferase activity.
Bate-Eya LT; Gierman HJ; Ebus ME; Koster J; Caron HN; Versteeg R; Dolman MEM; Molenaar JJ
Eur J Cancer; 2017 Apr; 75():63-72. PubMed ID: 28214660
[TBL] [Abstract][Full Text] [Related]
14. Synergistic Anti-Tumor Activity of EZH2 Inhibitors and Glucocorticoid Receptor Agonists in Models of Germinal Center Non-Hodgkin Lymphomas.
Knutson SK; Warholic NM; Johnston LD; Klaus CR; Wigle TJ; Iwanowicz D; Littlefield BA; Porter-Scott M; Smith JJ; Moyer MP; Copeland RA; Pollock RM; Kuntz KW; Raimondi A; Keilhack H
PLoS One; 2014; 9(12):e111840. PubMed ID: 25493630
[TBL] [Abstract][Full Text] [Related]
15. Acquisition of a single EZH2 D1 domain mutation confers acquired resistance to EZH2-targeted inhibitors.
Baker T; Nerle S; Pritchard J; Zhao B; Rivera VM; Garner A; Gonzalvez F
Oncotarget; 2015 Oct; 6(32):32646-55. PubMed ID: 26360609
[TBL] [Abstract][Full Text] [Related]
16. Oncogenic histone methyltransferase EZH2: A novel prognostic marker with therapeutic potential in endometrial cancer.
Oki S; Sone K; Oda K; Hamamoto R; Ikemura M; Maeda D; Takeuchi M; Tanikawa M; Mori-Uchino M; Nagasaka K; Miyasaka A; Kashiyama T; Ikeda Y; Arimoto T; Kuramoto H; Wada-Hiraike O; Kawana K; Fukayama M; Osuga Y; Fujii T
Oncotarget; 2017 Jun; 8(25):40402-40411. PubMed ID: 28418882
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of the Histone Methyltransferase EZH2 Enhances Protumor Monocyte Recruitment in Human Mesothelioma Spheroids.
Mola S; Pinton G; Erreni M; Corazzari M; De Andrea M; Grolla AA; Martini V; Moro L; Porta C
Int J Mol Sci; 2021 Apr; 22(9):. PubMed ID: 33922336
[TBL] [Abstract][Full Text] [Related]
18. [Effect of a novel EZH2 inhibitor GSK126 on prostate cancer cells].
Lin W; Chen Y; Zeng L; Ying R; Zhu F
Zhejiang Da Xue Xue Bao Yi Xue Ban; 2016 May; 45(4):356-363. PubMed ID: 27868408
[TBL] [Abstract][Full Text] [Related]
19. Enhancer of zeste homolog 2-catalysed H3K27 trimethylation plays a key role in acute-on-chronic liver failure via TNF-mediated pathway.
Zhou T; Sun Y; Li M; Ding Y; Yin R; Li Z; Xie Q; Bao S; Cai W
Cell Death Dis; 2018 May; 9(6):590. PubMed ID: 29789597
[TBL] [Abstract][Full Text] [Related]
20. The EZH2 inhibitor tazemetostat upregulates the expression of CCL17/TARC in B-cell lymphoma and enhances T-cell recruitment.
Yuan H; Nishikori M; Otsuka Y; Arima H; Kitawaki T; Takaori-Kondo A
Cancer Sci; 2021 Nov; 112(11):4604-4616. PubMed ID: 34449935
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
